Lepirudin as an alternative to "heparin allergy" during cardiopulmonary bypass
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,General Medicine,Surgery,Pulmonary and Respiratory Medicine
Link
http://link.springer.com/article/10.1186/1749-8090-6-44/fulltext.html
Reference21 articles.
1. Markwardt F: Hirudin: the promising antithrombotic. Cardiovasc Drug Rev. 1992, 10: 211-232.
2. Gardell SJ, Sanderson PE: Novel anticoagulants based on direct inhibition of thrombin and factor Xa. Coron Artery Dis. 1998, 9: 75-8 1.
3. Weitz JI, Huboda M, Massel D, Marganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990, 86: 385-391.
4. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, H G: Mueller-Velten and B. Pötzsch. Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia: A Prospective Study. Circulation. 1999, 99: 73-80.
5. Greinacher A, Lubenow N: Recombinant hirudin in clinical practice: Focus on lepirudin. Circulation. 2001, 103: 1479-1484.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy;Journal of Cardiothoracic Surgery;2023-09-11
2. Potential clinical applications of phytopharmaceuticals for the in‐patient management of coagulopathies in COVID ‐19;Phytotherapy Research;2022-02-11
3. Issues in Cardiac Surgery;Cardiac Anesthesia and Postoperative Care in the 21st Century;2022
4. High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood;Anesthesia & Analgesia;2020-08-20
5. Cardiopulmonary Bypass Without Heparin;Seminars in Cardiothoracic and Vascular Anesthesia;2016-02-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3